open access

Vol 52, No 2 (2021)
Editorial
Submitted: 2021-03-22
Accepted: 2021-03-22
Get Citation

TP53 mutations in chronic lymphocytic leukemia

Tadeusz Robak
DOI: 10.5603/AHP.2021.0012
·
Acta Haematol Pol 2021;52(2):75-76.

open access

Vol 52, No 2 (2021)
EDITORIAL
Submitted: 2021-03-22
Accepted: 2021-03-22

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

TP53 mutations in chronic lymphocytic leukemia

Journal

Acta Haematologica Polonica

Issue

Vol 52, No 2 (2021)

Article type

Editorial

Pages

75-76

DOI

10.5603/AHP.2021.0012

Bibliographic record

Acta Haematol Pol 2021;52(2):75-76.

Authors

Tadeusz Robak

References (10)
  1. Te Raa GD, Kater AP. TP53 dysfunction in CLL: implications for prognosis and treatment. Best Pract Res Clin Haematol. 2016; 29(1): 90–99.
  2. Eichhorst B, Robak T, Montserrat E, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32(1): 23–33.
  3. Dicker F, Herholz H, Schnittger S, et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia. 2009; 23(1): 117–124.
  4. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016; 17(6): 779–790.
  5. Malcikova J, Pavlova S, Kozubik KS, et al. TP53 mutation analysis in clinical practice: lessons from chronic lymphocytic leukemia. Hum Mutat. 2014; 35(6): 663–671.
  6. Pepek M, Pula B, Machnicki MM, et al. Results of Polish Adult Leukemia Study Group (PALG) project assessing TP53 mutations with next-generation sequencing technology in relapsed and refractory chronic lymphocytic leukemia patients — 18 months update. Acta Haematol Pol. 2021; 52(2): XX–XX.
  7. Rigolin GM, Saccenti E, Bassi C, et al. Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations. J Hematol Oncol. 2016; 9(1): 88.
  8. Malcikova J, Tausch E, Rossi D, et al. European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) — TP53 network. ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation. Leukemia. 2018; 32(5): 1070–1080.
  9. Kantorova B, Malcikova J, Smardova J, et al. TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different detection methods. Tumour Biol. 2015; 36(5): 3371–3380.
  10. Nadeu F, Delgado J, Royo C, et al. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. Blood. 2016; 127(17): 2122–2130.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl